4D Molecular Therapeutics (FDMT) said Thursday that the US Food and Drug Administration has granted the regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema.
The therapy is designed to provides multi-year sustained delivery of anti-VEGF, aflibercept and anti-VEGF-C, from the retina with a single intravitreal injection, the company said.
The RMAT designation, which is part of the 21st Century Cures Act, was created to expedite the development and review of regenerative medicine therapies, according to the announcement.
Price: 3.33, Change: -0.04, Percent Change: -1.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.